Floatz logo

ETHAMBUTOL

Mycobacterium Abscessus Pulmonary Disease

The University of QueenslandSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Mycobacterium Abscessus Pulmonary Disease cohort.

Asset / SponsorPhaseRating
RIFABUTIN
The University of Queensland
Phase 2CCC
Trimethoprim
The University of Queensland
Phase 2CCC
Molgramostim Nebulizer
Savara Inc.
Phase 2CCC
CEFOXITIN
The University of Queensland
Phase 2CCC
Amikacin
The University of Queensland
Phase 2CCC

View all 22 →

Same molecule, other indications

ETHAMBUTOL is also rated in:

tuberculosisDormant
BB
Indicative ·
69 / 100
View asset →
Mycobacterium avium complex diseaseDormant
B
Indicative ·
57 / 100
View asset →
obesity disorderDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →